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Abstract:
The contribution of the bone marrow (BM) immune microenvironment (TME) to acute myeloid leukemia (AML)
development is well-known, but its prognostic significance is still elusive. Indoleamine 2,3-dioxygenase
1 (IDO1), which is negatively regulated by the BIN1 proto-oncogene, is an interferon (IFN)- -inducible
mediator of immune tolerance. With the aim to develop a prognostic IDO1-based immune gene signature,
biological and clinical data of 732 patients with newly diagnosed, non-promyelocytic AML were retrieved
from public datasets and analyzed using established computational pipelines. Targeted transcriptomic
profiles of 24 diagnostic BM samples were analyzed using the NanoString's nCounter platform. BIN1 and
IDO1 were inversely correlated and individually predicted overall survival. PLXNC1, a semaphorin
receptor involved in inflammation and immune response, was the IDO1-interacting gene retaining the
strongest prognostic value. The incorporation of PLXNC1 into the 2-gene IDO1-BIN1 score gave rise to a
powerful immune gene signature predicting survival, especially in patients receiving chemotherapy. The
top differentially expressed genes between IDO1low and IDO-1high and between PLXNC1low and PLXNC1 high
cases further improved the prognostic value of IDO1 providing a 7 and 10-gene immune signature, highly
predictive of survival and correlating with AML mutational status at diagnosis. Taken together, our data
indicate that IDO1 is pivotal for the construction of an immune gene signature predictive of survival in
AML patients. Given the emerging role of immunotherapies for AML, our findings support the incorporation
of immune biomarkers into current AML classification and prognostication algorithms.
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 The semaphorin receptor PLXNC1 is an IDO1-interacting gene and a strong predictor of 
survival in acute myeloid leukemia (AML) 
 An IDO1-related immune gene signature, including PLXNC1, predicts survival in AML 
 
Abstract 
The contribution of the bone marrow (BM) immune microenvironment (TME) to acute myeloid 
leukemia (AML) development is well-known, but its prognostic significance is still elusive. 
Indoleamine 2,3-dioxygenase 1 (IDO1), which is negatively regulated by the BIN1 proto-
oncogene, is an interferon (IFN)--inducible mediator of immune tolerance. With the aim to 
develop a prognostic IDO1-based immune gene signature, biological and clinical data of 732 
patients with newly diagnosed, non-promyelocytic AML were retrieved from public datasets 
and analyzed using established computational pipelines. Targeted transcriptomic profiles of 24 
diagnostic BM samples were analyzed using the NanoString’s nCounter platform. BIN1 and 
IDO1 were inversely correlated and individually predicted overall survival. PLXNC1, a 
semaphorin receptor involved in inflammation and immune response, was the IDO1-interacting 
gene retaining the strongest prognostic value. The incorporation of PLXNC1 into the 2-gene 
IDO1-BIN1 score gave rise to a powerful immune gene signature predicting survival, especially 









 cases further improved the prognostic 
value of IDO1 providing a 7 and 10-gene immune signature, highly predictive of survival and 
correlating with AML mutational status at diagnosis. Taken together, our data indicate that 
IDO1 is pivotal for the construction of an immune gene signature predictive of survival in 
AML patients. Given the emerging role of immunotherapies for AML, our findings support the 
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Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematologic 
malignancy that progresses rapidly and originates from a rare population of leukemic stem 
cells. Despite intensive chemotherapy and stem cell transplantation, the outcome of AML has 
not changed substantially in the last decades. The estimated 5-year overall survival (OS) rate is 
approximately 30% and death rates have remained stable
1
. In this scenario, innovative 
strategies and tools are urgently needed to improve outcomes for AML patients.  
In many cancers, such as diffuse large B-cell lymphoma
2







 and lung adenocarcinoma
7,8
, the tumor microenvironment (TME) has been 
shown to retain a prognostic value that can be asserted by immune-specific gene expression 
patterns.
9,10
 However, the current risk classification
11
 of AML is exclusively focused on 
leukemic cell-intrinsic cytogenetic and molecular alterations, which have historically been 
known to impact on response to conventional chemotherapy and risk of relapse. Compelling 
preclinical data clearly demonstrate the impact of tolerogenic mechanisms played by TME in 
dysregulating patients’ immune response to AML cells. Very recently, the prognostic 
significance of immune landscape has been addressed in AML, revealing that immune-related 
genes may predict response to therapy and survival
12
. 
Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the rate-limiting step in tryptophan 
metabolism along the kynurenine pathway. In tumors, IDO1 is negatively controlled by the 
BIN1 tumor suppressor
13
, which in turn is regulated by the RBM25 splicing factor generating a 
dominant-negative BIN1 isoform that is unable to repress MYC activity
14
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shown that IDO1 is expressed in a significant proportion of AML patients at disease onset
15
 
where it promotes the establishment of an immunosuppressive TME through the induction of T 
regulatory cells (Tregs)
16–19
. Previous studies investigated the impact of IDO1 on AML 
survival. In particular, IDO1 mRNA expression in the bone marrow (BM), evaluated by gene 
expression profiling or quantitative real-time polymerase chain reaction (qRT-PCR) was a 
predictor of shorter survival
20,21
. Recently, an immunohistochemical score based on IDO1 
expression was shown to predict early mortality in AML
22
. Herein, we interrogated public 
AML transcriptomic datasets and profiled primary BM samples from newly diagnosed AML 
patients with the aim to identify an IDO1-related immune gene signature that may further refine 
our ability to predict survival. 
 
 
Materials and methods 
Data sources 
For the in-silico generation of a prognostic IDO1-associated gene signature, three publicly 
available independent gene expression datasets were used. Biological and clinical data of 982 
patients with newly diagnosed non-promyelocytic AML patients, including complete 
cytogenetic, immunophenotypic, and clinical annotations, were retrieved from The Cancer 
Genome Atlas (TCGA) profiling project, the HOVON (E-MTAB-3444) dataset
23
 and the 
GSE106291 dataset (available through Gene Expression Omnibus, GEO)24. The TCGA series 
consisted of RNA-sequencing data (Illumina HiSeq 2000) available through cBioPortal for 
Cancer Genomics at https://www.cbioportal.org/25,26 and Xena Platform at 
http://xena.ucsc.edu/
27
. In the TCGA-AML dataset, only patients treated with curative intent on 
a “7+3” chemotherapy backbone (n=123) were considered for survival analyses. 
The HOVON series (available through Array Express; E-MTAB-3444) consisted of gene array 
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Group and the Swiss Group for Clinical Cancer Research (HOVON/SAKK) AML-04, -04A, -
29, -32, -42, -42A, -43 and -92 protocols (available at http://www.hovon.nl). In particular, 
clinical and pathological data were available for 609 patients
28
 HOVON patients aged more 
than 65 years were excluded from survival analyses. Patients’ characteristics are summarized in 
Table 1 and 2.  
The GSE106291 dataset (available through Gene Expression Omnibus, GEO) consists of gene 
expression data by high throughput sequencing from AML patients treated in the AMLCG-
2008 (NCT01382147, n=210) and AMLG-1999 trials (NCT00266136, n=40). Survival data 
were available in 248/250 patients in the GSE106291 series. The results shown in this paper 
are in part based upon data retrieved from the Cancer Genome Atlas (TCGA) profiling 
project and the HOVON (E-MTAB-3444) dataset. The data referring to the validation 
cohort are included in the Gene Expression Omnibus database (accession number 
GSE146204). 
 
IDO1-related gene normalization and co-expression analysis 
The analysis of genes with a coordinated expression pattern in TCGA-AML was performed 
through the cBioPortal platform
25,26
. The top 5 genes correlated with IDO1 were, then, selected 
and their impact on survival was evaluated using the Kaplan-Meier method. 
 
Validation cohort 
Twenty-four BM samples from patients with non-promyelocytic AML were collected at 
diagnosis and were used to validate the correlation between IDO1 and PLXNC1 expression. 
Median age at diagnosis was 55 years; 18 patients were male and 6 were female (patients’ 
clinical data are summarized in Table 3). Patients provided written informed consent. The 
investigations were conducted in accordance with the Declaration of Helsinki. Approval was 
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Cox regression analysis and computation of gene prognostic signatures 
Gene expression was min-max normalized to a value between 0 and 1. The association between 
gene expression and survival time was evaluated using Cox regression analysis. Beta 
coefficients from Cox PH models were used to assign a prognostic weight to each individual 
gene in a given signature. According to a previously published formula
29
, we developed a gene 
signature calculated as the linear combination of mRNA expression weighted by the regression 
coefficient (β) derived from multivariate Cox regression analysis with overall survival as a 
dependent variable. Regarding the IDO1-BIN1-PLXNC1 signature, patients were stratified into 
3 groups (low score group, intermediate score group and high score group) using the 25° and 
75° percentiles of the score as cut-off. A summary of the key signatures used in this study is 
reported in Supplementary Table 1. 
 
Probe ID selection 
In the HOVON dataset, the following probe IDs were used for the analysis of mRNA 
expression: 210029_at (IDO1), 206470_at (PLXNC1), 210202_s_at (BIN1), 212028_at 
(RBM25), 209341_s_at (IKBK3), 204420_at (FOSL1), 223903_at (TLR9), 210321_at (GZMH), 
205495_s_at (GNLY), 217502_at (IFIT2), and 204747_at (IFIT3). 
 
Real-time polymerase chain reaction  
Total RNA was extracted from mononuclear cells isolated from the BM of our validation 
cohort (n=24) using the Qiagen RNeasy kit according to the manufacturer's protocol. Quality 
control of the isolated RNA was performed using an Agilent bioanalyzer and NanoDrop 8000 
(Thermo Scientific, Waltham MA, USA). An OD260/280 ratio between 1.8 and 2.2 and a RIN 
value above 9.0 was considered for further processing. For cDNA synthesis, 1 g of denatured 
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Promega, Madison WI, USA) in a 20 μl final volume according to the manufacturer’s 
instruction. qRT-PCR was performed in a 96-well Optical Reaction Plate using the ABI-
PRISM 7900 Sequence Detection System (Applied Biosystems, Foster City CA, USA). 
Threshold cycle (Ct) values were determined automatically. Relative quantification was 
calculated using ΔCt comparative method
30
. Primer probes for PLXNC1 Hs00194968_m1, 
IDO1 Hs00158027_m1 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
Hs00266705_g1 were purchased from Applied Biosystems.  
 
 
NanoString nCounter™ platform  
Gene expression analysis was performed on the nCounter™ platform (NanoString 
Technologies Inc., Seattle, WA)
31
 using the PanCancer IO 360™ Gene Expression Panel
32
. 150 
ng of total RNA from 24 primary BM samples was used in each reaction. Hybridization of 
probes was carried out at 65ᵒC for 20 hours. Post-hybridization samples were purified using a 
NanoString Prep Station and immobilized onto a cartridge. Raw data were acquired using the 
nCounter® FLEX Analysis System with a scanning resolution of 555 FOV using the probe 
annotation file NS_IO360_V1.0. Quality controls, data normalization and differential 
expression analysis were performed using the nSolver advanced analysis module (version 
2.0.115) according to the manufacturer’s instructions. The Benjamini-Yekutieli (B-Y) method 
was used to generate an adjusted p-value (BY.p.value).  
 
Pan-cancer analysis 
Survival meta-analyses of TCGA cancer datasets were performed using the GEPIA2 web-
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Deconvolution analysis of AML-TCGA and Genotype-Tissue Expression (GTEx) datasets was 
performed using the GEPIA2021
34
 web-server (http://gepia2021.cancer-pku.cn/) through the 
EPIC method
35
 to estimate the proportion of immune and stromal cells from bulk gene 
expression data. 
Statistical methods 
Differences between sets of data were considered statistically significant for P-values <0.05. 
Statistical analyses were performed using the IBM SPSS Statistics (version 25), GraphPad 
Prism software packages (version 7) and R (version 4.0.4). 
Results  
A two-gene BIN1-IDO1 signature predicts OS in AML 
In the attempt to develop an IDO1-related immune signature which predicts clinical outcome in 
AML, we initially focused on BIN1, a master regulator of IDO1 in solid tumors
13
, and we 
found that IDO1 and BIN1 mRNA expressions were anti-correlated (r = - 0.41, P<0.0001, 
Figure 1A). Of note, RMB25, known to be a key modulator of BIN1 expression
14
, correlated 
both with BIN1 (Pearson R = - 0.29, P<0.0001, Supplementary Figure 1A) and IDO1 
(Pearson R = 0.46, P<0.0001, Supplementary Figure 1B). We next investigated the impact of 
IDO1 and BIN1 expression on AML survival. To minimize any bias due to differences in 
treatment approaches (intensive versus non-intensive, curative versus palliative) and to increase 
comparability among patient groups, we stratified HOVON cases based on patient age. We 
analyzed only patients aged less than 65 years, thus reducing the likelihood of including 
patients who were not treated with curative intent. We plotted the normalized IDO1 and BIN1 
mRNA expression in a single score using a previously reported formula
29
 and split the HOVON 
cohort into three groups according to the score quartile. OS was significantly different among 
the three score groups (P<0.01, Figure 1B). With a median follow up of 8.1 years [95% CI, 7.0 
- 9.2], patients in the low and intermediate score groups showed significantly longer OS than 
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intermediate score group: median OS = 1.8 years [95% CI, 1.3 - 2.3], high score group: median 
OS = 1.1 years [95% CI, 0.8 - 1.4]). In particular, the comparison among high, intermediate, 
and low score groups showed a hazard ratio (HR) of 1.5 (95% CI, 1.1- 2.0, P<0.01). These data 
therefore indicate that an IDO1-centered gene signature may predict OS in AML. 
 
PLXNC1 correlates with IDO1 and affects OS both in TCGA- and HOVON-AML cases 
To identify other genes in the network that could be incorporated into the prognostic score 
based on IDO1-BIN1 signature, we performed a co-expression analysis on TCGA cases
25,26
 
(Table 4). This approach identified IDO2, CD1C, CD1E, XCR1, PLXNC1 as the top 5 co-
expressed genes. The median expression of each gene was selected as a cut-off to split TCGA-
AML patients into two groups (high and low) and was then correlated with patient survival. 
Interestingly, among the top 5 IDO1-correlated genes, only IDO2 and PLXNC1 showed a 
significant impact on AML survival in univariate analyses (log-rank P<0.05, Figures 1C and 
1D). The correlations between IDO1, IDO2 and PLXNC1 (IDO1 vs IDO2: r = - 0.27, 95% C.I. 
[0.19 to 0.33], P<0.0001, Figure 1E; IDO1 vs PLXNC1: r = - 0.25, 95% C.I. [- 0.33 to - 0.18], 
P<0.0001, Figure 1F) as well as their impact on AML survival were independently validated in 
the HOVON dataset (IDO2: log-rank P<0.05, Figure 1G and PLXNC1: log-rank P<0.001, 
Figure 1H). As shown by Cox regression analyses, the IDO1-PLXNC1 signature was the only 
predictor of survival (IDO1: β=0.68, HR=1.99 and P<0.05; PLXNC1: β=0.84, HR=2.32 and 
P<0.01). Taken together, these data indicate that PLXNC1 is a novel IDO1-related gene that 
stratifies survival. 
 
Incorporation of PLXNC1 into the IDO1-BIN1 score improves the predictive power of the 
gene signature 
Given the established interactions between IDO1, PLXNC1 and BIN1 and their potential impact 




 http://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2021004878/1823053/bloodadvances.2021004878.pdf by Sergio R




score, which was then tested for its prognostic value. The resulting IDO1-BIN1-PLXNC1 
signature was predictive of overall survival (IDO1: β=1.032, HR=2.81, P<0.01; BIN1: β=0.758, 
HR=2.13, P<0.05 and PLXNC1: β=0.820, HR 2.27, P<0.01, Table 5), which prompted us to 
split patients into three groups using score quartiles as cut-off.  
Kaplan Meier analysis showed a significantly different OS for the three score groups 
(P<0.001). In particular, among the 572 HOVON patients, the highest score predicted the 
shortest survival. With a median follow up of 8.1 years [95% CI, 7.0 – 9.2], low and 
intermediate score groups showed a median OS of 2.9 years [95% CI, 0.0 – 6.0] and 1.6 years 
[95% CI, 1.2 – 2.1], respectively, whereas high score group correlated with a median OS of 1.1 
years [95% CI, 0.8– 1.5], (Figure 2A). Intermediate and high score groups versus low score 
one showed hazard ratios (HR) of 1.2 (95% CI 1.0 - 1.6, P=NS) and 1.8 (95% C.I. 1.4 - 2.4, 
P<0.01), respectively. However, the IDO1-BIN1-PLXNC1 signature did not significantly 
stratify patients according to ELN cytogenetic risk groups (Supplementary Figure 2A-D). In 
FLT3-wild type patients score values resulted significantly higher than those of FLT3-mutated 
ones (P<0.01, Supplementary Figure 2E). Among FLT3-wild type patients, the score 
remained statistically significant (P<0.0001, Supplementary Figure 2F). Of note, IDO1-BIN1-
PLXNC1-based score was capable of predicting OS both in patients treated only with 
chemotherapy (Figure 2B) and in those who received allogeneic hematopoietic stem 
transplantation (HSCT) (Figure 2C). To validate these results, the score was implemented in 
the TCGA data set by using the same Cox regression coefficients derived from the analysis 
performed on the HOVON cases. Overall, the predictive ability of the score remained highly 
significant (P<0.01, Figure 2D). However, the score impacted on OS of patients who received 
only chemotherapy (P<0.0001, Figure 2E), whereas no statistically significant difference was 
observed in patients undergoing allogeneic HSCT (Figure 2F). We further confirmed the three 
different survival groups identified by IDO1-BIN1-PLXNC1 signature in the GSE106291 
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Taken together, these data suggest that IDO1-BIN1-PLXNC1 gene signature may predict OS in 
AML patients, especially when treated only with chemotherapy. 
 
Targeted immune transcriptomic profiling of IDO1 and PLXNC1 high/low patients uncovers 
non-overlapping pathways and identifies a parsimonious gene set predicting AML outcome. 
Firstly, a deconvolution analysis was applied to the AML-TCGA and Genotype-Tissue 
Expression (GTEx) datasets through the EPIC method
35
 to explore IDO1 and PLXNC1 gene 
sub-expression in single cell-types. Interestingly, both IDO1 and PLXNC1 expression by B-
cells, T cells and macrophages resulted to be higher in AML samples when compared to 
healthy donors bone marrow samples (Supplementary Figure 4A and 4B). 
We next profiled unfractionated BM samples from a cohort of 24 patients with newly 
diagnosed AML using the nCounter platform, which allows the quantitative measurement of 
mRNA species without RNA amplification. To identify transcriptional patterns associated with 
changes in IDO1 and PLXNC1 expression, the patient cohort was split according to the median 





samples (value threshold of 0.01; log2 fold-
change threshold of 1.4, Supplementary Table 2 and 3) showed negligible overlap (Figure 
3A), suggesting that PLXNC1 and IDO1 expression may reflect non-redundant biological 





samples was higher in TCGA-AML cases compared with blood 
samples from healthy donors available through the Genotype-Tissue Expression (GTEx) 
project (Figure 3B). Pathway enrichment analysis using the DE genes between PLXNC1
high/low
 
samples as an input showed that viral infection, apoptosis regulation, glucose metabolism and 
c-met signaling were among the most significantly enriched pathways in samples with high 
expression of PLXNC1 (Figure 3C). In contrast, samples with high IDO1 expression were 
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response pathways (Figure 3D). Notably, the top 20 DE genes between PLXNC1
high/low
 samples 
were able to stratify survival in TCGA-cases. In particular, patients with higher than median 
gene expression showed significantly worse survival estimates than patients with lower than 
median gene expression (HR=2.0; log-rank P=0.002; Figure 4A). In addition, the DE genes 
between IDO1
high/low
 samples were able to assist outcome prediction in TCGA-AML (HR=2.0; 
log-rank P=0.002; Figure 4B). 
In the attempt to refine our 20-gene signatures, we focused on genes that were individually 
associated with significant differences in OS in TCGA cases. Interestingly, IKBKB, FOSL1 and 
TLR9 in the PLXNC1
high/low
 signature and GZMH, GNLY, IFIT2 and IFIT3 in the IDO1
high/low
 
signature stratified patient survival (HR=2.4 and log-rank P<0.0001; HR=1.6 and log-rank 
P=0.03, respectively; Figures 4C and 4D). The ability to predict outcomes was improved by 




 signatures (HR=1.6 and log-
rank P=0.029; Figure 4E). As next step, we asked whether deregulated expression of the 7 DE 
genes correlated with specific molecular features in TCGA cases. As shown in Figure 4F, no 
mutations of the 7 DE genes were documented in TCGA patients. In contrast, abnormalities in 
the 7 genes utilized in the query (by default, non-synonymous mutations, fusions, 
amplifications and deep deletions) were detected in 28% of TCGA cases (Figure 4G) and were 
significantly enriched in patients with adverse-risk molecular features, including TP53 and 
KRAS mutations 
36
 (P=0.016 and P=0.019, respectively). Further analyses of mutual 
exclusivity and co-occurrence patterns indicated that CEBPA mutations, which correlate with 
more favorable prognosis 
36
, were negatively associated with abnormalities in the 7 DE genes 
(P=0.0159). Moreover, we added the IDO1, BIN1 and PLXNC1 genes to the previously 
discovered 7 DE genes. The combined 10-gene signature was highly predictive of AML 
outcome (HR=2.6 and log-rank P<0.0001; Figure 4H).  The 7- and 10-gene signatures also 
predicted survival in the HOVON dataset (respectively P<0.05, Supplementary Figure 5A 
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no statistically significant differences in survival emerged according to the 10-gene signature 
(Supplementary Figure 5C-E). Furthermore, regarding FLT3 mutational status, the 10-gene 
signature enabled survival prediction only in FLT3 wild-type patients (P<0.001, 
Supplementary Figure 5F).  
Finally, we performed a pan-cancer analysis of TCGA solid tumor types. The expression of 
genes in the PLXNC1-derived and IDO1-derived signatures in matched tumor samples and 
adjacent normal tissues is shown in Supplementary Figures 6 and 7. This analysis indicated 
that individual genes in the PLXNC1-derived signature may retain prognostic relevance also in 
selected solid tumor cell types, including low-grade glioma, and hepatocellular, lung and 
adrenocortical carcinoma (Supplementary Figure 8A). In contrast, the prognostic power of 
genes in the IDO1-derived signature was restricted to low-grade glioma, thymoma and uveal 
melanoma (Supplementary Figure 8B). Taken together, these data indicate that IDO1 and 
PLXNC1 are implicated in non-overlapping biological mechanisms and may refine the 
accuracy of survival prediction in AML. 
 
Discussion  
Our data indicate that IDO1 is pivotal for the construction of an immune gene signature 
predictive of survival in AML patients. Based on its well-known immunologic properties, 
IDO1 was used as a key input gene to further explore the immunogenomic AML landscape and 
to identify genes that could be incorporated into a novel prognostic signature for newly 
diagnosed AML. We identified a previously unexplored correlation between IDO1 and BIN1 in 
AML and we demonstrated that this 2-gene score predicts OS. Indeed, inclusion of the IDO1-
interacting gene PLXNC1 improved the predictive ability of the IDO1-BIN1 signature, 
especially in patients who received chemotherapy. This observation prompted us to explore the 
IDO1-related gene network in depth, leading to the identification of highly predictive 7 and 10-
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In solid tumors, BIN1 negatively regulates IDO1 expression at the level of IFN--related 
transcription program via STAT1- and NF-κB13. Herein, we report for the first time that a 
similar negative correlation between IDO1 and BIN1 mRNA expression exists in AML. 
Moreover, we showed that a low expression of the key BIN1-regulator RBM25 
14
 correlates 
with high BIN1 and low IDO1 levels in AML, suggesting a common molecular pathway in 
IDO1 gene regulation, which may be shared across tumors of different histological types and 
cell of origin. In line with a previous report
13
, our data highlight that IDO1 expression is mainly 
associated to IFN-related pathways. Of note, our study identified a novel set of IDO1-
interacting genes, among which PLXNC1 emerged as a crucial and master one. In myeloid 
precursors, PLXNC1 expression is restrained by the RUNX1 transcription factor and dependent 
on KIT signaling
37
. Although its function is still elusive, Plexin C1 as receptor for semaphorin 
7A
38
 dampens the acute inflammatory response through the regulation of dendritic cell (DC) 
activity and migration
38,39
. Our data expand to the AML setting the characterization of 
PLXNC1. In particular, PLXNC1 was co-regulated with genes involved in T-cell differentiation, 
lymphocyte proliferation and activation, consistently with the above-mentioned preferential 
activity of Plexin C1 in the activation of T-cell immune response via DCs. Overall, this 
analysis revealed an enrichment in pathways correlated with immune response, thus supporting 
our hypothesis that an IDO1-centered gene signature may be a useful tool to prognostically 
dissect AML immunological landscape.   
By first moving from the negative correlation between IDO1 and BIN1, we demonstrated that 
these two genes constitute a molecular signature, which may predict OS. The addition of 
PLXNC1 to IDO1 and BIN1 resulted in a more powerful gene immune signature predicting 
survival, which was further implemented leading to the identification of a highly predictive 7- 
and 10-gene immunological signature. The robustness of the proposed immune signatures is 
confirmed by the fact that they retain their predictive value when applied to independent AML 
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signature to stratify survival was highly significant especially when we analyzed patients who 
received chemotherapy. Although this finding warrants further investigation, it may suggest 
that, along with established leukemic cell-intrinsic chromosomal translocations and genetic 
mutations, cell-autonomous and immune-related factors, such as those deriving from the 
immune TME, may contribute to regulate response to conventional chemotherapy. Indeed, an 
increasing body of evidence has highlighted the immunomodulatory effects of some 
antineoplastic agents, especially anthracyclines, which may act as adjuvants of the immune 
system along with inducing anti-proliferative effects on tumor cells
40
. In AML, we reported 
that chemotherapy is capable to reshape leukemic microenvironment by activating immune 
effector T cells and, concomitantly, inducing IDO1-expressing tolerogenic DCs and Tregs
41
. 
These data support the notion that the immune composition of BM microenvironment may 
influence the response to chemotherapy.  
Of note, a close association between the immunological TME and cancer-intrinsic genomic 
alterations has been recently highlighted
42
 and correlated to the response to chemotherapy. In 
AML, a specific TME-related immunogenomic profile correlates with increased 
chemoresistance and with response to immunotherapy
43
 and a correlation between TP53 
mutations and an immunosuppressive TME has been recently established
44,45
. Of note, our 





 signatures were more frequently documented in patients 
with adverse-risk molecular features, including TP53 and KRAS mutations, whereas they were 
negatively correlated with CEBPA mutations, known to confer favorable prognosis and better 
response to chemotherapy. Consistently, higher levels of PLXNC1 were observed in AML 
patients with cytogenetic abnormalities, whereas lower mRNA levels were reported in patients 
with CEBPA mutations and with inv(16) or t(8;21)
46,47
.  
Regarding patients who received chemotherapy and allogeneic transplantation, the predictive 
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is not confirmed in the TCGA dataset. Although a formal demonstration was not the main focus 
of our work, we have argued that the differences in the predicting value of our score among 
patients who underwent allogeneic transplantation and those who received only chemotherapy 
may rely on the impact that allogeneic transplantation could exert on tumor immunologic 
microenvironment. 
In conclusion, our data shed light into the biological significance of immune-related gene 
networks in AML prognostication. In this scenario, IDO1 emerged as pivotal and paramount 
for the construction of powerful predictive immune gene signatures. In an era of emerging 
novel approaches targeting the immune system, our results highlight the need to integrate 
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Table 1 Overview of biological and clinical data referring to patients in the HOVON and TCGA 
datasets. 
  HOVON TCGA GSE106291 
Sex  
Female 294 56 129 
Male 315 67 119 
Fab       
AML-notM 1 0 N.A. 
M0 26 12 N.A. 
M1 134 38 N.A. 
M2 154 28 N.A. 
M4 111 29 N.A. 
M5 139 12 N.A. 
M6 9 2 N.A. 
M7 0 1 N.A. 
RAEB 5 0 N.A. 
RAEB-t 19 0 N.A. 
Unknown 11 1 N.A. 
BM blasts abundance at diagnosis 
 
 








Cytogenetic risk  
Adverse 123 26 N.A. 
Favorable 204 17 N.A. 
Intermediate 280 78 N.A. 
Not evaluable risk 2 2 N.A. 
Treatment  
Allogeneic HSCT 196 64 N.A. 
Autologous HSCT 91 6 N.A. 
Chemotherapy 320 53 N.A. 
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Table 2 Overview of mutational data referring to patients in the HOVON and the TCGA 
datasets. 
  HOVON TCGA GSE106291 
NPM1 status 
Wild-type 422 83 N.A. 
Mutated 183 40 N.A. 
Unknown 4 0 250 
FLT3 status  
Wild-type 441 88 N.A. 
Mutated 165 35 N.A. 
Unknown 3 0 250 
NRAS status  
Wild-type 509 112 N.A. 
Mutated 60 11 N.A. 
Unknown 40 0 250 
KRAS status      
Wild-type 483 120 N.A. 
Mutated 5 3 N.A. 
Unknown 121 0 250 
KIT status      
Wild-type 427 107 N.A. 
Mutated 20 6 N.A. 
Unknown 162 10 250 
ASXL1 status      
Wild-type 573 121 N.A. 
Mutated 31 2 N.A. 
Unknown 5 0 250 
IDH1 status      
Wild-type 528 108 N.A. 
Mutated 42 15 N.A. 
Unknown 39 0 250 
IDH2 status      
Wild-type 510 110 N.A. 
Mutated 60 13 N.A. 
Unknown 39 0 250 
 
 
Table 3 Overview of clinical data referring to validation cohort patients 
 
Sample type Sex 
Median 
age 




BM = 24 
Female = 6 
Male = 18 
55 
High = 7 
Intermediate = 7 
Low = 6 
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Table 4 Gene list resulting from IDO1-focused co-expression analyses of RNA-sequencing 








IDO2 8p11,21 0.45 P<0.001 P<0.001 
CD1C 1q23,1 0.39 P<0.001 P<0.01 
CD1E 1q23,1 0.38 P<0.001 P<0.01 
XCR1 3p21,31 0.38 P<0.001 P<0.01 





Table 5 Results of cox regression analysis including IDO1, BIN1 and PLXNC1 genes in the 
HOVON dataset. 
 
Genes Significance HR [95,0% CI] 
      
BIN1 P<0.05 2.13 [1.17 – 3.90] 
IDO1 P<0.01 2.81 [1.44 – 5.47] 
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Figure 1  IDO1-BIN1 signature predicts AML survival and may be refined by adding 
IDO1-interacting genes 
(A) Correlation between IDO1 and BIN1 gene expression values in the HOVON cases (r= - 
0.41, P<0.0001). (B) Kaplan-Meier estimates of OS in the HOVON cases according to the 
IDO1-BIN1 score (P<0.01). Patients were split into three different groups according to score 
quartiles. (C) Kaplan-Meier estimates of OS according to IDO2 expression in the TCGA-AML 
dataset (IDO2 median expression value used as cut-off, P<0.05). (D) Kaplan-Meier estimates 
of OS according to PLXNC1 expression in the TCGA-AML dataset (PLXNC1 median 
expression value used as cut-off, P<0.05). (E) Correlation between IDO1 and IDO2 gene 
expression values in the HOVON cases (r= 0.27, P<0.0001). (F) Correlation between IDO1 and 
PLXNC1 gene expression values in the HOVON cohort of patients (r= -0.25, P<0.0001). (G) 
Kaplan-Meier estimates of OS according to IDO2 expression in the HOVON dataset (IDO2 
median expression value used as cut-off, P<0.05). (H) Kaplan-Meier estimates of OS according 





Figure 2  IDO1-BIN1-PLXNC1 score predicts AML survival 
(A) PLXNC1 mRNA expression value was added to IDO1 and BIN1 mRNA expression values 
to generate a new signature. The figure shows Kaplan-Meier estimates of OS according to 
IDO1-BIN1-PLXNC1 score quartiles in the HOVON cohort of patients (P<0.0001). (B) 
Kaplan-Meier estimates of OS according to IDO1-BIN1-PLXNC1 score quartiles in patients of 
the HOVON cohort who received chemotherapy alone (P<0.001) or (C) received chemotherapy 
and allogeneic transplantation (P<0.05). (D) Kaplan-Meier estimates of OS according to IDO1-
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estimates of OS according to IDO1-BIN1-PLXNC1 score quartiles in patients of the TCGA-
AML dataset who received chemotherapy alone (P<0.01) or (F) who received chemotherapy 
and allogeneic transplantation (P = not significant). 
 
Figure 3  IDO1 and PLXNC1 are overexpressed and may reflect independent biological 
processes in AML 
(A) The expression of the top 20 DE genes between PLXNC1high/low and IDO1high/low samples was higher 
in TCGA-AML cases compared with blood samples from healthy donors available through the 
Genotype-Tissue Expression (GTEx) project (B) Representation of the top 20 differentially 




samples (P value threshold of 
0.01; log2 fold-change threshold of 1.4). (C) Enrichment analysis showing the top significant 
pathways associated with DE genes between PLXNC1
high/low
 samples. (D) Enrichment analysis 











(A) Kaplan-Meier estimates of OS according to the signature composed by the top 20 
differentially expressed (DE) expressed genes between PLXNC1
high/low
 samples in the TCGA-
AML cases (median used as cut-off, P<0.05). (B) Kaplan-Meier estimates of OS according to 
the signature composed by the top 20 DE genes between IDO1
high/low
 samples in the TCGA-
AML cases (median used as cut-off, P<0.01). (C) Kaplan-Meier estimates of OS according to 
the signature composed by the top 3 DE genes (IKBKB, FOSL1 and TLR9) between 
PLXNC1
high/low
 samples in the TCGA-AML cases (median used as cut-off, P<0.0001). (D) 
Kaplan-Meier estimates of OS according to the signature composed by the top 4 DE genes 
(GZMH, GNLY, IFIT2 and IFIT3) between IDO1
high/low
 samples in TCGA-AML cases (median 
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composed by the top 3 DE genes from the PLXNC1
high/low
 signature (IKBKB, FOSL1 and TLR9) 
and the top 4 DE genes from IDO1
high/low
 signature (GZMH, GNLY, IFIT2 and IFIT3) in the 
TCGA-AML dataset (median used as cut-off, P<0.05). (F) Representation of genetic alterations 




 signatures (IKBKB, 
FOSL1, TLR9, GZMH, GNLY, IFIT2 and IFIT3) in the TCGA-AML dataset. (G) Comparison 
of frequency of mutations between samples with abnormalities (mRNA high/low) vs without 





(IKBKB, FOSL1, TLR9, GZMH, GNLY, IFIT2 and IFIT3). (H) Kaplan-Meier estimates of OS 





 signatures (IKBKB, FOSL1, TLR9, GZMH, GNLY, IFIT2 and 
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